Philippines considering cutting existing tariffs for pharmaceutical products

10 September 2006

As part of a comprehensive review of the nation's duties program, the Philippines is planning to cut some of its existing tariffs for pharmaceutical products while lowering those on raw material imports, according to Tariff Commissioner Edgardo Abon, reported by the Philippine Star newspaper. He said the review is now in its final stages, with only a few minor issues to be resolved.

Mr Abon said he was hopeful that a new tariff program would be ready for signing by the country's President, Gloria Arroya, during the next congressional break, noting that "we just want to make sure that everything is OK when the President signs it."

However, he admitted that there has still been no final decision on how long the new tariff program would be effective but, most likely, it would be for a three to four-year period. Mr Abon's own recommendation is for this to be in force for five years, in order to give businesses a longer period for planning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight